Get the Stockscreener App
237.27
2.46%
5.69
After Hours:
233.23
-4.04
-1.70%
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $237.27, with a volume of 2.32M.
It is up +2.46% in the last 24 hours and down -1.77% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$231.58
Open:
$231
24h Volume:
2.32M
Relative Volume:
2.61
Market Cap:
$34.83B
Revenue:
$4.81B
Net Income/Loss:
$1.11B
P/E Ratio:
38.52
EPS:
6.16
Net Cash Flow:
$1.35B
1W Performance:
-0.52%
1M Performance:
-1.77%
6M Performance:
+11.25%
1Y Performance:
+36.39%
1-Day Range:
$231.00
$238.60
1-Week Range:
$229.94
$245.19
52-Week Range:
$164.12
$260.49
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
237.27 | 34.83B | 4.81B | 1.11B | 1.35B | 7.55 |
|
ISRG
Intuitive Surgical Inc
|
524.43 | 186.79B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
227.68 | 65.83B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
84.76 | 41.92B | 9.76B | 1.16B | 665.00M | 2.34 |
|
WST
West Pharmaceutical Services Inc
|
331.40 | 24.00B | 2.88B | 499.60M | 321.60M | 6.74 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Y Intercept Hong Kong Ltd Reduces Position in ResMed Inc. (NYSE:RMD) - MarketBeat
$18.97 Bn Mechanical Ventilator Market Opportunities and - GlobeNewswire
ResMed Inc.'s (NYSE:RMD) institutional investors lost 4.5% last week but have benefitted from longer-term gains - Simply Wall St
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
YieldBoost ResMed From 0.9% To 6.8% Using Options - Nasdaq
ResMed Inc Director Expands Stock Holdings - MSN
XTX Topco Ltd Has $301,000 Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
With 74% institutional ownership, ResMed Inc. (NYSE:RMD) is a favorite amongst the big guns - Yahoo Finance
Franklin Resources Inc. Increases Stock Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
2,216 Shares in ResMed Inc. (NYSE:RMD) Acquired by World Investment Advisors LLC - MarketBeat
ResMed's SWOT analysis: sleep tech giant faces GLP-1 threat, AI opportunity - Investing.com
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
2 ASX companies with the traits of a long-term winner - Morningstar.com.au
Is ResMed Stock Outperforming the Nasdaq? - Nasdaq
Is ResMed Stock Outperforming The Nasdaq? - Barchart
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
Assistive Technology Market Is Booming Worldwide 2024-2031: Dynavox Systems LLC., Invacare Corporation, ResMed - EIN News
Weight-loss drugs draw Americans back to the doctor - Marketscreener.com
The Global Medical Cannula Market Is Poised for Significant Growth USD 447.0 Million by 2034 at a 6.9% of CAGR, driven by Rising Demand for Medical Procedures and Advanced Healthcare Solutions | FMI - GlobeNewswire Inc.
What is William Blair's Estimate for ResMed Q2 Earnings? - MarketBeat
Stifel Initiates Coverage of ResMed Inc.Depositary Receipt () (RSMDF) with Hold Recommendation - MSN
Wellington Management Group LLP Purchases 15,772 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc. (NYSE:RMD) Receives $227.91 Average PT from Brokerages - MarketBeat
Toronto Dominion Bank Has $12.02 Million Stock Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
American Trust Makes New $690,000 Investment in ResMed Inc. (NYSE:RMD) - MarketBeat
Virtu Financial LLC Decreases Stake in ResMed Inc. (NYSE:RMD) - MarketBeat
We Ran A Stock Scan For Earnings Growth And ResMed (NYSE:RMD) Passed With Ease - Yahoo Finance
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
Why ResMed (RMD) is a Top Value Stock for the Long-Term - Yahoo Finance
ResMed (NYSE:RMD) Now Covered by Analysts at Stifel Nicolaus - MarketBeat
ResMed, The Company Behind Making Sleep Apnea Machines, has Developed The $120 Kontor Head Strap For The Apple Vision Pro To Alleviate Head Strain - Wccftech
Zacks.com featured highlights include InterDigital, ResMed, Greenbrier Companies, Charles River Associates and Kontoor Brands - Yahoo Finance
ResMed Inc. stock falls Thursday, underperforms market - MarketWatch
Geode Capital Management LLC Acquires 380,383 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc. (NYSE:RMD) Shares Purchased by Nomura Asset Management Co. Ltd. - MarketBeat
ResMed Inc. stock rises Wednesday, still underperforms market - MarketWatch
ResMed Inc (RMD) CFO Brett Sandercock Sells 1,000 Shares - GuruFocus.com
ResMed CFO Sandercock sells $244,230 in stock By Investing.com - Investing.com South Africa
ResMed CFO Sandercock sells $244,230 in stock - Investing.com
ResMed's SWOT analysis: sleep tech giant faces GLP-1 drug challenge - Investing.com
Stifel Financial Corp Has $14 Million Stock Position in ResMed Inc. (NYSE:RMD) - MarketBeat
National Bank of Canada FI Acquires 19,120 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
'Huge opportunity' ahead for this ASX 200 healthcare stock - MSN
13,712 Shares in ResMed Inc. (NYSE:RMD) Bought by Executive Wealth Management LLC - MarketBeat
iA Global Asset Management Inc. Has $1.40 Million Stock Position in ResMed Inc. (NYSE:RMD) - MarketBeat
What is Zacks Research's Forecast for ResMed Q2 Earnings? - MarketBeat
William Blair Brokers Boost Earnings Estimates for ResMed - MarketBeat
Returns on Capital Paint A Bright Future For ResMed (NYSE:RMD) - Yahoo Finance
Insiders At ResMed Sold US$17m In Stock, Alluding To Potential Weakness - Simply Wall St
Quantinno Capital Management LP Has $6.02 Million Stake in ResMed Inc. (NYSE:RMD) - MarketBeat
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):